A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cervical Squamous Cell Carcinoma
- Squamous Non-small-cell Lung Cancer
- Colorectal Cancer
- Intrahepatic Cholangiocarcinoma
- Urothelial Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alentis Therapeutics AG
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic Comprehensive Cancer Center · Phoenix, AZ
California · 1
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
Connecticut · 1
- Yale Comprehensive Cancer Center · New Haven, CT
Illinois · 1
- The University of Chicago Medical Center - Oncology · Chicago, IL
Kentucky · 1
- Norton Cancer Institute - Norton Healthcare Pavilion · Louisville, KY
New Jersey · 1
- John Theurer Cancer Center · Hackensack, NJ
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- Next Oncology-Oncology · San Antonio, TX
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.